300434 Sichuan Goldstone
- 10.29
- +0.19+1.88%
Sichuan Goldstone News
The number of A-share flu Concept stocks with limit rise increases: Shijiazhuang Yiling Pharmaceutical and more than 10 other stocks hit the limit rise, while Shandong Xinhua Pharmaceutical is nearing the limit rise.
Gelonghui, January 6 - Currently, it is winter, and the influenza virus is making a comeback, drawing attention to flu medications. In the A-share market, flu Concept stocks have further increased their gains in the afternoon, with more stocks hitting the daily limit. As of now, Sichuan Goldstone has reached the daily limit of 20%, Shanxi Zhendong Pharmaceutical has risen nearly 15%, Xiangxue Pharmaceutical has increased over 11%, Henan Taloph Pharmaceutical Stock, North China Pharmaceutical, Luoxin Pharmaceuticals Group Stock, Xinjiang Bai Hua Cun Pharma Tech, Shandong Lukang Pharmaceutical, Northeast Pharmaceutical Group, Shijiazhuang Yiling Pharmaceutical, Hainan Huluwa Pharmaceutical Group, Harbin Pharmaceutical Group, and Guangdong Zhongsheng Pharmaceutical have all hit the daily limit of 10%, while Shandong Xinhua Pharmaceutical is close to reaching its daily limit.
Sichuan Goldstone (300434.SZ): Yafeng Pharmaceutical Factory has obtained the high-tech enterprise certificate.
Gelonghui, December 31st丨Sichuan Goldstone (300434.SZ) announced that its wholly-owned subsidiary, Zhejiang Yafeng Pharmaceutical Co., Ltd. (referred to as "Yafeng Pharmaceutical"), has been recognized as a high-tech enterprise. Recently, Yafeng Pharmaceutical received the "High-Tech Enterprise Certificate" issued jointly by the Zhejiang Provincial Taxation Bureau, Zhejiang Provincial Department of Finance, and Zhejiang Provincial Department of Economy and Information Technology (Certificate No.: GR202433001388, date of issue: December 6, 2024, valid for three years).
Sichuan Goldstone (300434.SZ): Deer Pharmaceutical's hydrochloride amorolfine ointment has successfully passed the pharmaceutical GMP compliance inspection.
On December 31, Gelonghui announced that Sichuan Goldstone (300434.SZ) recently received the "Pharmaceutical GMP Compliance Inspection Notice" (No: Zhe2024 No. 0269) issued by the Zhejiang Provincial Drug Administration for its wholly-owned subsidiary, Zhejiang Deer Pharmaceutical Co., Ltd. (referred to as "Deer Pharmaceutical"). Hydrochloride Amorolfine Solution is an over-the-counter medication for dermatology, used to treat nail infections caused by sensitive fungi. Deer Pharmaceutical's Hydrochloride Amorolfine Solution was approved by the National Medical Products Administration in June 2006.
Express News | Sichuan Goldstone: The wholly-owned subsidiary's pharmaceutical has passed the GMP compliance inspection.
A-share pharmaceutical stocks are rebounding, zhejiang shengda bio-pharm hits the limit up.
On November 20th, Shengda Bio-Pharmaceuticals hit the daily limit up, Sichuan Goldstone rose by over 8%, Apichope Pharmaceutical, Haisco Pharmaceutical Group, Zhejiang Ausun Pharmaceutical rose by over 7%, Jiangsu Hengrui Pharmaceuticals rose by over 3%.
Express News | Sichuan Goldstone Pharmaceutical: Wholly-owned subsidiary obtains the registration certificate for oseltamivir phosphate capsules.
Jinshi Asia Pharmaceutical: Report for the third quarter of 2024
Sichuan Goldstone (300434.SZ): Does not involve the production of PBO materials
Goldstone Pharma (300434.SZ) stated on the investor interaction platform on September 12 that the company is not involved in the production of PBO materials and is currently conducting research and development work on vacuum coating equipment for the surface metalization treatment of PBO materials.
Jinshi Asia Pharmaceutical: 2024 Semi-Annual Report Summary
Jinshi Asia Pharmaceutical: 2024 Semi-Annual Report
Sichuan Goldstone Pharmaceuticals (300434.SZ) plans to distribute dividends of 1.1 yuan per 10 shares in 2023, with ex-rights and ex-dividends on June 28.
Sichuan Goldstone Pharmaceutical Co., Ltd. (stock code: 300434.SZ) announced that the company plans to distribute a cash dividend of 1.1 yuan (including tax) per 10 shares to all shareholders in 2023. The equity distribution registration day for this distribution is June 27, 2024, and the ex-rights and ex-dividend date is June 28, 2024.
Jinshi Asia Pharmaceutical (300434.SZ): Not involved in the field of low-altitude economy
Gelonghui, May 29丨Jinshi Yayao (300434.SZ) said on the investor interactive platform that our company's business currently involves the medical and health sector and the new materials, machinery and equipment sector, and is not currently involved in the low-altitude economy.
Express News | Jinshi Yayao: The fiber wire continuous coating production line project is still in the pilot phase
Jinshi Asia Pharmaceutical (300434.SZ): AI technology has not been applied in drug research and development
Gelonghui, April 30 | Jinshi Yayao (300434.SZ) said on the investor interactive platform that currently the application of AI technology in drug development mainly focuses on drug design and optimization, prediction of adverse reactions and clinical trials, and patient recruitment. The company has not yet applied AI technology to drug research and development. The company is actively promoting drug research and development through multiple channels such as independent research and development, outsourced R&D, and document acquisition. Please pay attention to the company's announcements regarding the company's drug development.
Jinshi Pharmaceutical (300434.SZ) announced first-quarter results, net profit of 898.16,200 yuan, a year-on-year decrease of 37.39%
Jinshi Pharmaceutical (300434.SZ) released its report for the first quarter of 2024. The company achieved operating revenue during the period...
Express News | Jinshi Asia Pharmaceutical: The company currently has no oseltamivir related products on the market
Jinshi Asia Pharmaceutical (300434.SZ): Plans to jointly invest in Lingye Pharmaceutical with related parties
Gelonghui, December 28 | Jinshi Ya Pharmaceutical (300434.SZ) announced that the company recently signed a “Capital Increase Agreement on Hangzhou Lingye Pharmaceutical Technology Development Co., Ltd.” (“Dragon Fruit Investment”), Hangzhou Dragon Fruit Investment Management Co., Ltd. (“Dragon Fruit Investment”), and natural person Ms. Gao Yaping. The company and Ms. Gao Yaping and Dragon Fruit Investment plan to invest a total of RMB 694.885,700 to subscribe to Lingye Pharmaceutical with an additional registered capital of RMB 27.72,89.4 million. Among them, the company plans to use RMB 3154.0
Jinshi Yayao (300434.SZ): In terms of childhood pneumonia, the main production and marketing varieties include azithromycin dry suspension, ambroxol hydrochloride oral solution, etc.
Gelonghui, December 12|Jinshi Yayao (300434.SZ) said on the investor interactive platform that in terms of colds and fevers in children, our company mainly produces and sells pediatric aminophen granules, ibuprofen granules, cold and fever-clearing granules, pentane root granules, antiviral oral solution, etc.; in terms of childhood pneumonia, the main products and marketing varieties include azithromycin dry suspensions, amoxicillin granules, cefixime granules, ambroxol hydrochloride oral solution, etc.; it can provide different symptoms for children Medications provide symptomatic treatment.
Jinshi Yayao (300434.SZ): Net profit increased 89.45% to 156 million yuan in the first half of the year
Gelonghui, August 28: Jinshi Yayao (300434.SZ) announced its 2023 semi-annual report. Operating revenue for the reporting period was 634 million yuan, up 32.18% year on year; net profit attributable to shareholders of listed companies was 156 million yuan, up 89.45% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1,496 billion yuan, up 137.42% year on year; basic earnings per share were 0.3876 yuan.
Jinshi Subdrug (300434.SZ): There are currently no weight loss products on sale
GLONGHUI August 9丨Some investors asked Jinshi Asiayao (300434.SZ), “Now that foreign diet pills are very popular, can the company sell diet medicine products?” Jinshi Yayao replied that in the medical and health sector, the product line that the company is focusing on covers the fields of cold and fever relief, gastrointestinal digestion, throat cleansing and cough relief, antibacterial and anti-inflammatory, and nutritional supplements. Currently, there are no weight loss products on sale.
No Data